Edwards Lifesciences (NYSE: EW) exec nets 13,457 shares, 7,469 withheld
Rhea-AI Filing Summary
Edwards Lifesciences Corp executive Donald E. Bobo Jr., CVP, Strategy/Corporate Development, reported the vesting and exercise of performance-based restricted stock units into 13,457 shares of common stock on May 11, 2026, after the board’s Compensation and Governance Committee certified 167.70% of the target award for vesting as of that date.
To satisfy related tax liability, 7,469 shares of common stock were withheld at $79.96 per share. Following these equity compensation transactions, he directly holds 32,766.2532 shares of Edwards Lifesciences common stock, alongside indirect holdings of 38,969.5756 shares in a 401(k) plan and 121,756 shares held by a trust.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 5,988 shares
Net Buy
5 txns
Insider
BOBO DONALD E JR
Role
CVP,Strategy/Corp Development
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance Rights | 13,457 | $0.00 | $0.00 |
| Exercise | Common Stock | 13,457 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 7,469 | $79.96 | $597K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Performance Rights — 0 shares (Direct);
Common Stock — 32,766.2532 shares (Direct);
Common Stock — 38,969.5756 shares (Indirect, 401(k));
Common Stock — 121,756 shares (Indirect, By Trust)
Footnotes (2)
- F1. On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4.
- F2. These Performance Rights expire on May 10, 2030.
Key Figures
Shares acquired from performance rights: 13,457 shares
Shares withheld for taxes: 7,469 shares
Tax withholding price: $79.96 per share
+5 more
8 metrics
Shares acquired from performance rights
13,457 shares
Common stock received on May 11, 2026 upon exercise of performance-based units
Shares withheld for taxes
7,469 shares
Common shares withheld at $79.96 per share in a tax-withholding disposition on May 11, 2026
Tax withholding price
$79.96 per share
Per-share value used for the 7,469-share tax-withholding transaction
Direct common stock holdings
32,766.2532 shares
Direct Edwards Lifesciences common stock position after the reported transactions
Indirect 401(k) holdings
38,969.5756 shares
Edwards Lifesciences common stock held indirectly through a 401(k) plan as of May 11, 2026
Indirect trust holdings
121,756 shares
Edwards Lifesciences common stock held indirectly by a trust as of May 11, 2026
Performance award vesting percentage
167.70% of target shares
Vesting level approved by the Compensation and Governance Committee for the May 11, 2023 grant
Performance rights expiration
May 10, 2030
Expiration date stated for the Performance Rights linked to the vested units
Key Terms
Performance Rights, restricted stock units, performance-based vesting requirements, tax-withholding disposition, +1 more
5 terms
Performance Rights financial
"These Performance Rights expire on May 10, 2030."
Performance rights are conditional awards that give employees or executives the promise of receiving company shares or cash only if the business meets specific targets or survives for a set period. They work like a bonus you only get when certain goals are hit, so they matter to investors because they can increase the number of shares outstanding (dilution), signal management’s incentives and confidence in future results, and affect per-share earnings and valuation.
restricted stock units financial
"shares covered by restricted stock units with performance-based vesting requirements"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
performance-based vesting requirements financial
"restricted stock units with performance-based vesting requirements over a three-year performance period"
tax-withholding disposition financial
"transaction_action": "tax-withholding disposition""
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
401(k) financial
"nature_of_ownership": "401(k)""
A 401(k) is a type of retirement savings plan offered by employers that allows workers to set aside a portion of their paycheck before taxes are taken out. The money saved in a 401(k) can grow over time through investments, helping individuals build funds for their future retirement. It matters to investors because it provides a tax-advantaged way to save and invest for long-term financial security.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Donald E. Bobo Jr. report in Edwards Lifesciences (EW) Form 4?
Donald E. Bobo Jr. reported the vesting and exercise of performance-based units into 13,457 common shares on May 11, 2026. The Compensation and Governance Committee approved vesting at 167.70% of the target award for a three-year performance period.
What performance conditions applied to the Edwards Lifesciences (EW) award?
The award consisted of restricted stock units with performance-based vesting requirements over a three-year period starting May 11, 2023. On May 6, 2026, the board committee determined that 167.70% of the target number of shares would vest as of May 11, 2026.
Were any derivative securities exercised or canceled in the EW Form 4?
Yes. Performance Rights covering 13,457 underlying common shares were exercised or converted on May 11, 2026, resulting in common stock delivery and the derivative position going to zero for that award as reflected in the filing’s transaction details.
When do the Edwards Lifesciences (EW) Performance Rights mentioned in the filing expire?
The Performance Rights associated with this equity award are stated to expire on May 10, 2030. The vested portion, equal to 167.70% of the target shares, converted into 13,457 common shares as of the May 11, 2026 vesting date.